{"links":{"feed":"https://www.erudio.com/reports/m23-385-nct05599984/feed.json","html":"https://www.erudio.com/reports/m23-385-nct05599984","json":"https://www.erudio.com/reports/m23-385-nct05599984.json","markdown":"https://www.erudio.com/reports/m23-385-nct05599984.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"m23-385-nct05599984"}},"request":"https://www.erudio.com/contact?report=m23-385-nct05599984"},"offer":{"cited_clinicians":11,"cited_commentary_sources":18,"verified_hcp_statements":69,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":14},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"m23-385-nct05599984"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=m23-385-nct05599984","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/m23-385-nct05599984","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 69 verified statements · 37 from 11 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-21T01:46:10.813405Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":15,"no_commentary_found":8},"aspects":[{"claim_count":6,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":3,"title":"Primary endpoint: Percentage of Participants With Adverse Events (AE)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":0,"title":"Primary endpoint: Maximum Observed Serum/Plasma Concentration (Cmax) of ABBV-706"},{"claim_count":0,"coverage":"no_commentary_found","id":"T3","registry_field":"outcomesModule.primaryOutcomes[2]","source_count":0,"title":"Primary endpoint: Time to Cmax (Tmax) of ABBV-706"},{"claim_count":0,"coverage":"no_commentary_found","id":"T4","registry_field":"outcomesModule.primaryOutcomes[3]","source_count":0,"title":"Primary endpoint: Terminal Phase Elimination Half-Life (t1/2) of ABBV-706"},{"claim_count":0,"coverage":"no_commentary_found","id":"T5","registry_field":"outcomesModule.primaryOutcomes[4]","source_count":0,"title":"Primary endpoint: Area Under the Serum/Plasma Concentration-Time Curve (AUC) of ABBV-706"},{"claim_count":0,"coverage":"no_commentary_found","id":"T6","registry_field":"outcomesModule.primaryOutcomes[5]","source_count":0,"title":"Primary endpoint: Antidrug Antibodies (ADAs)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T7","registry_field":"outcomesModule.primaryOutcomes[6]","source_count":0,"title":"Primary endpoint: Neutralizing Antibodies (nAbs)"},{"claim_count":16,"coverage":"discussed","id":"T8","registry_field":"outcomesModule.primaryOutcomes[7]","source_count":10,"title":"Primary endpoint: Percentage of Participants with Objective Response, for Participants with Extracranial Solid Tumors"},{"claim_count":5,"coverage":"discussed","id":"T9","registry_field":"outcomesModule.primaryOutcomes[8]","source_count":2,"title":"Primary endpoint: Recommended Phase 2 Dose (RP2D) of ABBV-706"},{"claim_count":0,"coverage":"no_commentary_found","id":"T10","registry_field":"outcomesModule.primaryOutcomes[9]","source_count":0,"title":"Primary endpoint: Percentage of Participants with Objective Response for Participants with Central Nervous System (CNS) Tumors"},{"claim_count":1,"coverage":"discussed","id":"T11","registry_field":"outcomesModule.primaryOutcomes[10]","source_count":1,"title":"Primary endpoint: Duration of response (DOR) for Participants with Confirmed CR/PR"},{"claim_count":0,"coverage":"no_commentary_found","id":"T12","registry_field":"outcomesModule.primaryOutcomes[11]","source_count":0,"title":"Primary endpoint: Percentage of Participants with Clinical Benefit"},{"claim_count":4,"coverage":"discussed","id":"T13","registry_field":"outcomesModule.primaryOutcomes[12]","source_count":4,"title":"Primary endpoint: Progression-Free Survival (PFS)"},{"claim_count":7,"coverage":"discussed","id":"T14","registry_field":"outcomesModule.primaryOutcomes[13]","source_count":6,"title":"Primary endpoint: Overall survival (OS)"},{"claim_count":11,"coverage":"discussed","id":"T15","registry_field":"conditionsModule","source_count":4,"title":"Population and setting"},{"claim_count":8,"coverage":"discussed","id":"T16","registry_field":"armsInterventionsModule.armGroups","source_count":3,"title":"The comparison"},{"claim_count":7,"coverage":"discussed","id":"T17","registry_field":"outcomesModule","source_count":4,"title":"Safety and tolerability"},{"claim_count":5,"coverage":"discussed","id":"T18","registry_field":"designModule","source_count":3,"title":"Design and conduct"},{"claim_count":9,"coverage":"discussed","id":"A1","source_count":7,"title":"SEZ6 rationale, perceived promise and reactions to dissemination"},{"claim_count":4,"coverage":"discussed","id":"A2","source_count":4,"title":"Patient-selection hypotheses and exploratory biomarkers"},{"claim_count":3,"coverage":"discussed","id":"A3","source_count":2,"title":"Confirmatory development and a proposed post-tarlatamab sequence"},{"claim_count":3,"coverage":"discussed","id":"A4","source_count":2,"title":"Prospective trial access and patient-support implications"},{"claim_count":1,"coverage":"discussed","id":"A5","source_count":1,"title":"Symptomatic brain metastases: local therapy versus tarlatamab"}],"counts":{"beyond_population_findings":1,"beyond_population_statements":2,"cited_clinicians":11,"cited_clinicians_by_role":{"physician":4,"physician, Medical oncology":7},"cited_physicians":11,"cited_sources":20,"claims_by_expression_type":{"comparison":4,"experience":1,"interpretation":26,"opinion":19,"primary_context":5,"question":1,"restatement":9,"uncertainty":2,"unspecified":2},"claims_by_kind":{"objective_result":2,"protocol_statement":2,"publication_statement":23,"source_observation":42},"clinician_statements":37,"evidence_units":57,"findings":10,"people_cited":14,"people_identity_verified":14,"people_total":14,"screened_sources":29,"verified_claims":69},"findings_index":[{"cited_clinicians":3,"id":"F1","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":4,"views":4},"limitations":4,"links":{"context":0,"support":8},"ma_question":true,"named_voices":3,"passages":6,"sources":4,"sources_by_kind":{"commentary":2,"media":1,"publication":1}},"title":"ABBV-706: most clinicians highlight safety with budigalimab; one relays deaths","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-2426a9bac3bdcd535b71"],"clause":"one relays deaths","holders":1},"cited_claim_ids":["claim-7360ddca2e08e0bc4dd0","claim-fc6c880cb10e0a8af514","claim-410397b6469a1dc9b4b6"],"clinicians":true,"holders":2,"speakers":3,"view":"reading"},"evidence_line":"8 statements from 3 speakers in 4 sources, 1 of them a podcast or video","holder_line":"2 of the 3 named speakers in this finding hold this view, each a confirmed clinician; 1 of the 3 holds its caveat, “one relays deaths”"},{"cited_clinicians":5,"id":"F2","structure":{"claims":14,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":6,"views":7},"limitations":3,"links":{"context":2,"support":17},"ma_question":true,"named_voices":6,"passages":15,"sources":9,"sources_by_kind":{"commentary":7,"media":1,"publication":1}},"title":"ABBV-706 alone: most speakers highlight ORR, but some clinicians flag small numbers","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-a65e75525551647567f9","claim-78e2527ff3d379c055df"],"clause":"some clinicians flag small numbers","holders":2},"cited_claim_ids":["claim-7360ddca2e08e0bc4dd0","claim-2426a9bac3bdcd535b71","claim-748207f0cb1a6bf1da34","claim-9082bde5b12f77ea9477","claim-a65e75525551647567f9","claim-578467909ae5a65a7c32","claim-cbda97f2cdbeb084e711"],"clinicians":false,"holders":5,"speakers":6,"view":"reading"},"evidence_line":"14 statements from 6 speakers in 9 sources, 1 of them a podcast or video","holder_line":"5 of the 6 named speakers in this finding hold this view; 2 of them hold its caveat, “some clinicians flag small numbers”"},{"cited_clinicians":2,"id":"F3","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":6,"views":4},"limitations":3,"links":{"context":0,"support":12},"ma_question":true,"named_voices":2,"passages":9,"sources":5,"sources_by_kind":{"commentary":3,"media":1,"publication":1}},"title":"ABBV-706 monotherapy dose: how a clinician frames the efficacy–safety balance","title_holders":{"cited_claim_ids":["claim-342f04dc322371b957eb"],"clinicians":true,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"10 statements from 2 speakers in 5 sources, 1 of them a podcast or video","holder_line":"1 of the 2 named speakers in this finding holds this view, a confirmed clinician"},{"cited_clinicians":3,"id":"F4","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":5},"limitations":3,"links":{"context":0,"support":8},"ma_question":true,"named_voices":3,"passages":6,"sources":4,"sources_by_kind":{"commentary":2,"media":1,"publication":1}},"title":"ABBV-706 + budigalimab: what speakers say","evidence_line":"7 statements from 3 speakers in 4 sources, 1 of them a podcast or video"},{"cited_clinicians":2,"id":"F5","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":2,"views":2},"limitations":3,"links":{"context":1,"support":7},"ma_question":true,"named_voices":3,"passages":5,"sources":5,"sources_by_kind":{"commentary":4,"publication":1}},"title":"Subtype and prior Cisplatin: what a speaker asks; a clinician notes a ctDNA link","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-ecad5137745c363fffb9","claim-cbda97f2cdbeb084e711"],"clause":"a clinician notes a ctDNA link","holders":1},"cited_claim_ids":["claim-77e34edf8770e8c92164"],"clinicians":false,"holders":1,"speakers":3,"view":"reading"},"evidence_line":"6 statements from 3 speakers in 5 sources","holder_line":"1 of the 3 named speakers in this finding holds this view; 1 of the 3 holds its caveat, “a clinician notes a ctDNA link”"},{"cited_clinicians":3,"id":"F6","structure":{"claims":7,"claims_by_group":{"comparisons":1,"experience":1,"questions":0,"restated":0,"views":5},"limitations":3,"links":{"context":1,"support":8},"ma_question":true,"named_voices":3,"passages":7,"sources":4,"sources_by_kind":{"commentary":3,"media":1}},"title":"Other NENs: what clinicians highlight in early ABBV-706 activity and unmet need","title_holders":{"cited_claim_ids":["claim-bcca5b50cfd43d6c08d9","claim-ed1e63ca4839b65ca0da","claim-38d6dceaa48f40f757dd","claim-d772fe1fdba279597439","claim-87d30c103c8123f93229"],"clinicians":true,"holders":3,"speakers":3,"view":"reading"},"evidence_line":"7 statements from 3 speakers in 4 sources, 1 of them a podcast or video","holder_line":"3 of the 3 named speakers in this finding hold this view, each a confirmed clinician"},{"cited_clinicians":2,"id":"F7","structure":{"claims":5,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":1,"views":3},"limitations":2,"links":{"context":0,"support":5},"ma_question":true,"named_voices":2,"passages":4,"sources":3,"sources_by_kind":{"commentary":1,"media":1,"publication":1}},"title":"ABBV-706: a clinician seeks larger trials; one sees scope if tarlatamab fails","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-1f9a7e011ef60568de75"],"clause":"one sees scope if tarlatamab fails","holders":1},"cited_claim_ids":["claim-d40c5b40d5124d84d43c"],"clinicians":true,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"5 statements from 2 speakers in 3 sources, 1 of them a podcast or video","holder_line":"1 of the 2 named speakers in this finding holds this view, a confirmed clinician; 1 of the 2 holds its caveat, “one sees scope if tarlatamab fails”"},{"cited_clinicians":5,"id":"F8","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":1,"views":7},"limitations":3,"links":{"context":0,"support":11},"ma_question":false,"named_voices":6,"passages":8,"sources":7,"sources_by_kind":{"commentary":5,"media":1,"publication":1}},"title":"SEZ6: why most speakers welcome development; some clinicians welcome the phase 1 paper","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-3aa280c6416ecf9c4908","claim-9497be9bb974f385d475"],"clause":"some clinicians welcome the phase 1 paper","holders":2},"cited_claim_ids":["claim-aa742af1cfff56c55d4f","claim-6214daa49f189cf9ec0c","claim-b7e6a35a171c44fb4094","claim-bfc188edeb48a063fcb4"],"clinicians":false,"holders":4,"speakers":6,"view":"reading"},"evidence_line":"9 statements from 6 speakers in 7 sources, 1 of them a podcast or video","holder_line":"4 of the 6 named speakers in this finding hold this view; 2 of the 6 hold its caveat, “some clinicians welcome the phase 1 paper”"},{"cited_clinicians":1,"id":"F9","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":3},"limitations":3,"links":{"context":0,"support":4},"ma_question":true,"named_voices":1,"passages":4,"sources":3,"sources_by_kind":{"commentary":1,"media":1,"registry":1}},"title":"ABBV-706 trials: why a clinician links future access to local SCLC burden","title_holders":{"cited_claim_ids":["claim-f6762dd7476ea61c6b5c"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"4 statements from 1 speaker in 3 sources, 1 of them a podcast or video","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician"},{"cited_clinicians":1,"id":"F10","population":"beyond","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":1},"limitations":3,"links":{"context":0,"support":2},"ma_question":true,"named_voices":1,"passages":2,"sources":2,"sources_by_kind":{"commentary":1,"publication":1}},"title":"Symptomatic brain metastases: why a clinician favors RT/WBRT over tarlatamab","title_holders":{"cited_claim_ids":["claim-4e14cba70a67e735e71e"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"2 statements from 1 speaker in 2 sources","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician"}],"open_question":{"basis":"From finding F1 (8 statements from 3 speakers in 4 sources)","cited_claim_ids":["claim-7360ddca2e08e0bc4dd0","claim-2426a9bac3bdcd535b71","claim-8c4ae941af79943337f9","claim-fc6c880cb10e0a8af514","claim-410397b6469a1dc9b4b6","claim-4f716e9982e55f6b9013","claim-1d9b065bfae0eeff1af7","claim-78e2527ff3d379c055df"],"finding_ids":["F1"],"question":"What do clinicians still need to see in larger cohorts to assess severe hematologic toxicity and pneumonitis/ILD risk with ABBV-706 monotherapy and its combination with budigalimab in relapsed/refractory SCLC?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"One speaker calls toxicity manageable; an X account also relays severe toxicity and deaths"},{"id":"section-2","level":2,"title":"Speakers welcome the monotherapy signal; one X account stresses small numbers"},{"id":"section-3","level":2,"title":"An X relay frames the selected monotherapy dose as an efficacy–safety balance"},{"id":"section-4","level":2,"title":"One speaker sees the budigalimab combination as feasible and worth further study"},{"id":"section-5","level":2,"title":"One X account asks about subtype and prior cisplatin; another relays a ctDNA association"},{"id":"section-6","level":2,"title":"Speakers see promise in other neuroendocrine neoplasms, particularly LCNEC"},{"id":"section-7","level":2,"title":"One X account seeks larger-study confirmation; a speaker envisages a role after tarlatamab"},{"id":"section-8","level":2,"title":"X accounts welcome SEZ6 development and publication of the phase 1 evidence"},{"id":"section-9","level":2,"title":"One X account connects future trial access to local SCLC burden"},{"id":"section-10","level":2,"title":"Beyond the trial population"},{"id":"section-11","level":3,"title":"One X account favors RT/WBRT over tarlatamab for symptomatic brain metastases"},{"id":"section-12","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, non randomized, sequential, phase1","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":3}],"id":"T1","label":"Primary endpoint: Percentage of Participants With Adverse Events (AE)"},{"findings":[],"id":"T2","label":"Primary endpoint: Maximum Observed Serum/Plasma Concentration (Cmax) of ABBV-706"},{"findings":[],"id":"T3","label":"Primary endpoint: Time to Cmax (Tmax) of ABBV-706"},{"findings":[],"id":"T4","label":"Primary endpoint: Terminal Phase Elimination Half-Life (t1/2) of ABBV-706"},{"findings":[],"id":"T5","label":"Primary endpoint: Area Under the Serum/Plasma Concentration-Time Curve (AUC) of ABBV-706"},{"findings":[],"id":"T6","label":"Primary endpoint: Antidrug Antibodies (ADAs)"},{"findings":[],"id":"T7","label":"Primary endpoint: Neutralizing Antibodies (nAbs)"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":8},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":4},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":4}],"id":"T8","label":"Primary endpoint: Percentage of Participants with Objective Response, for Participants with Extracranial Solid Tumors"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":1}],"id":"T9","label":"Primary endpoint: Recommended Phase 2 Dose (RP2D) of ABBV-706"},{"findings":[],"id":"T10","label":"Primary endpoint: Percentage of Participants with Objective Response for Participants with Central Nervous System (CNS) Tumors"},{"findings":[{"id":"F2","shared_claims":1}],"id":"T11","label":"Primary endpoint: Duration of response (DOR) for Participants with Confirmed CR/PR"},{"findings":[],"id":"T12","label":"Primary endpoint: Percentage of Participants with Clinical Benefit"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2},{"id":"F4","shared_claims":2},{"id":"F5","shared_claims":2}],"id":"T13","label":"Primary endpoint: Progression-Free Survival (PFS)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":5},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":2}],"id":"T14","label":"Primary endpoint: Overall survival (OS)"},{"findings":[{"id":"F2","shared_claims":4},{"id":"F6","shared_claims":7},{"id":"F7","shared_claims":1},{"id":"F8","shared_claims":1}],"id":"T15","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":4}],"id":"T16","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":3}],"id":"T17","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F6","shared_claims":1}],"id":"T18","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-21T01:46:10.813405Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-21T01:58:45Z","record_hash":"d10d23c7b367e1e65f7d3927527d52977235a9b29c5047e9cde347166d7beadf","release_hash":"21cac369df7eb44e4b8f174c14ed6d20f1ba9e2de857fac29ed20c0e0b02be61","report_id":"erudio-nct05599984","run_id":"a7831b60-34a8-4008-9cf0-66d514d1b5b2","schema_version":"5.0","slug":"m23-385-nct05599984","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"A medical oncologist supports further study of M23-385 because of responses despite platinum resistance, but their pulmonary reassurance applies only to the budigalimab combination. Fatal treatment-related pneumonitis was reported with monotherapy; these accounts do not demonstrate disagreement within the same cohort. Another medical oncologist qualifies their favorable reading by stressing small cohorts. Survival observations remain preliminary, and neither budigalimab’s added benefit nor benefit after tarlatamab is established.","examples":[],"meta_description":"29 sources screened · 69 verified statements (37 from clinicians verified by NPI or staff page) from 20 sources · 10 findings. Updated Nov 21, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-21T01:58:45Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":29},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a remark on uncertain cohort attribution of the treatment-related mortality statement.","15 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 17 sources about other trials or topics are not included.","Many commentary passages identify ABBV-706 and a relevant setting rather than NCT05599984. Their clinical relevance does not make every numerical summary an independently identified result of this trial.","The linked publication describes preliminary phase 1 efficacy without a standard-of-care comparator or efficacy hypothesis testing. It separately describes a randomized dose-optimization component.","Safety summaries use different populations and adverse-event categories. Small combination-cohort reassurance cannot be generalized to monotherapy, and all reported safety figures cannot be reconciled from these statements.","Repeated posts, reposts and presentation relays are not independent clinical appraisals. A favorable publication reaction is not necessarily an efficacy or practice-adoption judgment.","Intracranial efficacy, validated patient-selection biomarkers and efficacy after tarlatamab remain incompletely addressed.","No separate protocol or exact product labels for ABBV-706 or budigalimab were available in the sources reviewed; this report does not establish regulatory status or approved-use boundaries."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":1,"registry":1,"regulatory":0,"x_thread":17,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":18,"methods":1,"results":1},"count":20,"evidence_window":{"end":"2026-11-13","start":"2023-04-07"},"retrieval_snapshot":"2026-11-21T01:02:52.225304Z","timeline":[{"count":1,"week":"2023-W14"},{"count":1,"week":"2024-W26"},{"count":1,"week":"2025-W23"},{"count":1,"week":"2025-W36"},{"count":1,"week":"2026-W21"},{"count":10,"week":"2026-W23"},{"count":1,"week":"2026-W43"},{"count":1,"week":"2026-W44"},{"count":1,"week":"2026-W46"}],"undated_sources":2},"quote_policies":[{"id":"clinicaltrials:NCT05599984:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05599984:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:42225988","quote_policy":"short_quote_link_out"},{"id":"openfda:93edf309-993c-48ec-be90-27d89c86b62b:20261112","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-t55lzfcrbvpl5linz44t6dic-3lnp6gct2is2n","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1644365204749180928:2fe092bb-65e9-4db9-942b-3555ce959dcf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1760747419082609039:e6168730-9b4b-484f-92da-965fdc499c38","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1806132160476356646:a3fd366d-0a0a-4dbf-9525-7ac934a891b7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929569096712048823:1683e6d5-d73a-4a09-9291-88145ba628fc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1963246356488720468:ed82e23e-a0e4-4cab-9124-c115facadcff","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1964278051123925374:3a514ceb-b107-44b6-b170-87d961dc90ae","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2048779201285963930:c747ec81-4854-472e-a93b-4a63ea833625","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2057935967164797232:e3b3aad8-9335-4d40-9110-5c8e251c11ee","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2058208833927839803:d685e725-3a90-4365-af6a-5caf1c611d58","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061551106757439840:72d2c314-96b8-41be-8596-d0000dc2ef44","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061551190207537421:59b6bf45-2c52-4cb1-a975-2bf6b6f290e1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061551895315980573:c4e7fdea-d723-44d4-af19-4cf0137f1836","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061551897559830826:d4fffa27-e504-47f5-8980-f946fa495675","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061552150052745292:f3c953db-dfa8-4918-9ad0-2c4c30ceb06e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061552360971993172:3ee62cfd-9816-483f-a837-b9aaee4bc63c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061552561686008194:b85ac5b5-e169-4b49-b3d9-c68fb7d8f407","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061555506636791977:77b1aaf3-5836-424c-bcc4-2feec25a92db","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061556080186957862:7649e1be-c297-4dd4-ad83-a4320d052aa9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061558019842855347:facff8c4-a61d-49a8-85da-9c3d68e7cfb7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061562463712141755:875eb818-69c6-409d-8c89-7e2b464863ec","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061590002358718571:d5557eab-d1de-4d80-aec3-63abfb7e164c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061593221923307832:1f143d89-67f2-4c6e-80e6-37c73211919b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061771329120960517:96bf1bd1-59a9-4885-b9ae-61a2748e6162","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2063272398825349272:5a2c2bd0-a30a-4395-88e2-ba9063dd365a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103847064245239830:63027182-5edd-4a99-b6e9-dbb14d83c2d4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112906754736427418:e32c4a89-2c0a-4a0b-94fa-36bfdbcad1ca","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114648589230322025:9312d18e-64ca-4dd6-846e-f025f453b55e","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:9qj7AJgzXDE","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":27,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":29},"count":29,"evidence_window":{"end":"2026-11-13","start":"2023-04-07"},"retrieval_snapshot":"2026-11-21T01:02:52.225304Z","timeline":[{"count":1,"week":"2023-W14"},{"count":1,"week":"2024-W08"},{"count":1,"week":"2024-W26"},{"count":1,"week":"2025-W17"},{"count":1,"week":"2025-W23"},{"count":2,"week":"2025-W36"},{"count":1,"week":"2026-W18"},{"count":2,"week":"2026-W21"},{"count":15,"week":"2026-W23"},{"count":1,"week":"2026-W39"},{"count":1,"week":"2026-W43"},{"count":1,"week":"2026-W44"},{"count":1,"week":"2026-W46"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":26,"registry":1,"regulatory":0,"x_thread":22,"x_video":0,"youtube":20}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":[{"abstracts":1,"label":"AACR Annual Meeting 2026","slug":"aacr26","sources":0},{"abstracts":1,"label":"2026 ASCO Annual Meeting","slug":"asco26","sources":0},{"abstracts":3,"label":"IASLC 2026 World Conference on Lung Cancer","slug":"wclc26","sources":0},{"abstracts":1,"label":"ESMO Congress 2026","slug":"esmo26","sources":0}],"drugs":[{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"turmetabart adizutecan","slug":"turmetabart-adizutecan"},{"brand_names":["Platinol"],"label":"cisplatin","slug":"cisplatin"},{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"budigalimab","slug":"budigalimab"},{"brand_names":["Paraplatin"],"label":"carboplatin","slug":"carboplatin"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Advanced solid tumors","slug":"advanced-solid-tumors"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"aliases":["Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors","A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors"],"brief_title":"Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Advanced Solid Tumors"],"display_condition":"advanced solid tumors","display_interventions":[["ABBV-706"],["ABBV-706","budigalimab"],["ABBV-706","platinum-based chemotherapy"]],"enrollment":{"count":288,"type":"ACTUAL"},"interventions":[{"name":"ABBV-706","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Cisplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Budigalimab","synonyms":["ABBV-181"],"type":"DRUG"},{"name":"Carboplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT05599984","official_title":"A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE1"],"primary_completion_date":{"date":"2027-11","type":"ESTIMATED"},"primary_endpoints":[{"description":"An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.","measure":"Percentage of Participants With Adverse Events (AE)","timeFrame":"Up to Approximately 2 Years"},{"description":"Maximum observed serum/plasma concentration of ABBV-706.","measure":"Maximum Observed Serum/Plasma Concentration (Cmax) of ABBV-706","timeFrame":"Up to Approximately 2 Years"},{"description":"Time to Cmax of ABBV-706.","measure":"Time to Cmax (Tmax) of ABBV-706","timeFrame":"Up to Approximately 2 Years"},{"description":"Terminal phase elimination half-life (t1/2) of ABBV-706.","measure":"Terminal Phase Elimination Half-Life (t1/2) of ABBV-706","timeFrame":"Up to Approximately 2 Years"},{"description":"Area under the serum/plasma concentration-time curve of ABBV-706.","measure":"Area Under the Serum/Plasma Concentration-Time Curve (AUC) of ABBV-706","timeFrame":"Up to Approximately 2 Years"},{"description":"Incidence and concentration of anti-drug antibodies.","measure":"Antidrug Antibodies (ADAs)","timeFrame":"Up to Approximately 2 Years"},{"description":"Incidence and concentration of neutralizing antibodies.","measure":"Neutralizing Antibodies (nAbs)","timeFrame":"Up to Approximately 2 Years"},{"description":"Objective response is defined as participants achieving a confirmed best overall response of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 for for extracranial solid tumors per investigator assessment.","measure":"Percentage of Participants with Objective Response, for Participants with Extracranial Solid Tumors","timeFrame":"Up to Approximately 2 Years"},{"description":"The RP2D will be determined using all available information, including, but not limited to, AEs, dose-limiting toxicities, pharmacokinetic parameters, clinical laboratory tests, and efficacy measures.","measure":"Recommended Phase 2 Dose (RP2D) of ABBV-706","timeFrame":"Up to Approximately 2 Years"},{"description":"Objective response is as participants achieving a confirmed best overall response of CR and PR according to Response Assessment for Neuro-Oncology (RANO), version 1.1 for CNS tumors per investigator assessment.","measure":"Percentage of Participants with Objective Response for Participants with Central Nervous System (CNS) Tumors","timeFrame":"Up to Approximately 2 Years"},{"description":"For participants achieving a confirmed CR/PR, DOR is defined as the time from the initial response of CR/PR to disease progression or death of any cause, whichever occurs earlier.","measure":"Duration of response (DOR) for Participants with Confirmed CR/PR","timeFrame":"Up to Approximately 2 Years"},{"description":"Clinical benefit is defined as a participant achieving CR/PR, or Stable Disease (SD).","measure":"Percentage of Participants with Clinical Benefit","timeFrame":"Up to Approximately 2 Years"},{"description":"PFS is defined as time from first study treatment to a documented disease progression, as determined by the investigator, or death due to any cause, whichever occurs earlier.","measure":"Progression-Free Survival (PFS)","timeFrame":"Up to Approximately 2 Years"},{"description":"OS is defined as time from first study treatment to death due to any cause.","measure":"Overall survival (OS)","timeFrame":"Up to Approximately 2 Years"}],"registered_date":{"date":"2022-10-31","type":"ACTUAL"},"registry_last_updated":"2026-05-07","registry_url":"https://clinicaltrials.gov/study/NCT05599984","short_name":"M23-385","short_name_basis":"sponsor_study_id","sponsor":"AbbVie","start_date":{"date":"2022-12-05","type":"ACTUAL"},"study_design":"interventional, non randomized, sequential, phase1","study_ids":[{"id":"M23-385","type":"sponsor_study_id"},{"id":"2023-504598-18-00","type":"ctis"}],"study_type":"INTERVENTIONAL"}}}